Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of inducement stock options to new employees. The company issued an aggregate of 36,400 stock options with an exercise price of $6.96 per share, matching the closing price on August 4, 2025.

The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term and follow a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.

CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees an aggregate of 36,400 options to purchase shares of the company’s common stock at an exercise price of $6.96 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, August 4, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What stock options did Fulcrum Therapeutics (FULC) grant to new employees in August 2025?

Fulcrum granted 36,400 stock options to new employees at an exercise price of $6.96 per share, with a ten-year term and four-year vesting schedule.

What is the vesting schedule for FULC's August 2025 employee stock options?

The options vest over four years, with 25% vesting after the first year and 6.25% vesting quarterly over the following three years, subject to continued employment.

What is the exercise price for Fulcrum Therapeutics' August 2025 inducement grants?

The exercise price is $6.96 per share, which was the closing price of Fulcrum's common stock on August 4, 2025.

Under which plan were the FULC inducement grants issued?

The stock options were granted under Fulcrum's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).